The biotechnology index correlation suggests "ocgn stock forecast 2025" could outperform sector averages if Ocugen secures breakthrough designation for its lead candidates. Current beta near 1.6 indicates above-market volatility levels, favoring active traders. Stay updated when valuation signals shift by adding Ocugen to your watchlist or portfolio . Alternatively, explore our screener to discover other companies that fit your criteria. Currently patients with GA in the United States have only one option available, an anti-complement therapy, which requires multiple injections and only addresses one aspect of the disease. Ocugen believes that OCU410 addresses multiple aspects of the disease beyond the complement pathway and has the potential to change the treatment paradigm for GA. By tracking patent filings, analysts believe "ocgn stock forecast 2025" may gain incremental valuation boosts if intellectual property coverage expands into broader therapeutic areas.